FDAnews Drug Daily Bulletin

SUSTAINED 3.4% ANNUAL SALES GROWTH IN THE PROSTATE CANCER DRUG MARKET WILL BE DRIVEN BY DEVELOPMENT OF NEW THERAPIES

June 8, 2006
A A

Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sustained annual growth of more than 3.4% in sales of prostate cancer therapies from 2005 to 2015 will be driven primarily by new entries to the market that will add to, rather than replace, existing therapies in the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan.
PR Newswire